<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01059929</url>
  </required_header>
  <id_info>
    <org_study_id>16865B</org_study_id>
    <nct_id>NCT01059929</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)</brief_title>
  <official_title>A Double-blinded Randomized Controlled Trial of Dexmedetomidine Versus Propofol for Sedation in Mechanically Ventilated Medical Intensive Care Unit Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized controlled trial to compare propofol to dexmedetomidine for prolonged
      sedation (&gt; 24 hours) in critically ill patients who require mechanical ventilation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanically ventilated critically ill patients are routinely given sedative and analgesic
      medications to relieve pain and anxiety associated with intubation, mechanical ventilation,
      and critical care in general. While integral in minimizing discomfort, these medications may
      increase mechanical ventilation time, the duration of intensive care unit (ICU) stay, ICU
      complications (e.g. delirium, ventilator associated pneumonia, venous thromboembolism), the
      morbidity associated with critical illness, and patient mortality. This study compares two
      sedative medications that have been used in patients who require a mechanical ventilator.
      Enrolled patients will be randomly assigned to receive propofol or dexmedetomidine for
      sedation while they require ventilatory support. All patients will also receive the pain
      medication fentanyl as needed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    drug and placebo unavailable
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Days With Delirium</measure>
    <time_frame>daily up to 28 days</time_frame>
    <description>delirium assessment using CAM-ICU</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Efficacy According to Richmond Agitation Sedation Scale (RASS) Score</measure>
    <time_frame>Daily up to day 28</time_frame>
    <description>Richmond Agitation Sedation Scale (RASS). This is a validated scale that measures level of sedation. The scale ranges from -5 to +4. -5 refers to a state where one is unarousable, +4 refers to a state where one is combative. The median and inter-quartile range over all daily assessments will be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Completing Mobility Milestones</measure>
    <time_frame>Daily through day 28</time_frame>
    <description>Milestones: sitting upright independently, standing independently, transfer to chair, marching in place, ambulating independently</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days on Ventilator</measure>
    <time_frame>60 days from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in ICU</measure>
    <time_frame>60 days from enollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ICU Complications</measure>
    <time_frame>daily through day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Fentanyl</measure>
    <time_frame>during infusion of study medication up to day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Midazolam</measure>
    <time_frame>during infusion of study medication through day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in Hospital</measure>
    <time_frame>60 days from enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Completing Activities of Daily Living</measure>
    <time_frame>daily through day 28</time_frame>
    <description>activities of daily living: eating, bathing, dressing, grooming, toileting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Medication Effects</measure>
    <time_frame>duration of infusion of study medication up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Mechanical Ventilation</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Physical and Occupational Therapy</intervention_name>
    <description>Daily therapy sessions targeting range of motion, strength, and mobility</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years old

          -  mechanically ventilated through endotracheal tube

          -  anticipated need for ventilation &gt; 48 hours

          -  requiring sedative/analgesic medication

        Exclusion Criteria:

          -  on mechanical ventilator &gt; 96 hours

          -  primary neurologic disease

          -  post cardiac arrest

          -  do not speak English (assessment only English language validated)

          -  pregnancy or lactation

          -  active myocardial ischemia

          -  second or third degree heart block

          -  pancreatitis

          -  elevated serum triglycerides (&gt; 400 mg/dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John P Kress, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>January 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2010</study_first_posted>
  <results_first_submitted>November 1, 2016</results_first_submitted>
  <results_first_submitted_qc>July 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 3, 2018</results_first_posted>
  <last_update_submitted>July 2, 2018</last_update_submitted>
  <last_update_submitted_qc>July 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypnotics and Sedatives</keyword>
  <keyword>Respiration, Artificial</keyword>
  <keyword>Ventilators, Mechanical</keyword>
  <keyword>Critical care</keyword>
  <keyword>Intensive care</keyword>
  <keyword>Physical therapy</keyword>
  <keyword>Occupational therapy</keyword>
  <keyword>Sedative medications</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexmedetomidine</title>
          <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
        </group>
        <group group_id="P2">
          <title>Propofol</title>
          <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexmedetomidine</title>
          <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
        </group>
        <group group_id="B2">
          <title>Propofol</title>
          <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.5" lower_limit="33" upper_limit="87"/>
                    <measurement group_id="B2" value="67" lower_limit="21" upper_limit="89"/>
                    <measurement group_id="B3" value="63.8" lower_limit="21" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Days With Delirium</title>
        <description>delirium assessment using CAM-ICU</description>
        <time_frame>daily up to 28 days</time_frame>
        <population>Study terminated early due to inability to maintain study drug supply in investigational pharmacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Days With Delirium</title>
          <description>delirium assessment using CAM-ICU</description>
          <population>Study terminated early due to inability to maintain study drug supply in investigational pharmacy.</population>
          <units>proportion of days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0.71"/>
                    <measurement group_id="O2" value=".33" lower_limit="0.13" upper_limit="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Efficacy According to Richmond Agitation Sedation Scale (RASS) Score</title>
        <description>Richmond Agitation Sedation Scale (RASS). This is a validated scale that measures level of sedation. The scale ranges from -5 to +4. -5 refers to a state where one is unarousable, +4 refers to a state where one is combative. The median and inter-quartile range over all daily assessments will be provided.</description>
        <time_frame>Daily up to day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Efficacy According to Richmond Agitation Sedation Scale (RASS) Score</title>
          <description>Richmond Agitation Sedation Scale (RASS). This is a validated scale that measures level of sedation. The scale ranges from -5 to +4. -5 refers to a state where one is unarousable, +4 refers to a state where one is combative. The median and inter-quartile range over all daily assessments will be provided.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-1" upper_limit="-0.57"/>
                    <measurement group_id="O2" value="-1.6" lower_limit="-3.23" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Completing Mobility Milestones</title>
        <description>Milestones: sitting upright independently, standing independently, transfer to chair, marching in place, ambulating independently</description>
        <time_frame>Daily through day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Completing Mobility Milestones</title>
          <description>Milestones: sitting upright independently, standing independently, transfer to chair, marching in place, ambulating independently</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days on Ventilator</title>
        <time_frame>60 days from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Days on Ventilator</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" lower_limit="2.28" upper_limit="16.6"/>
                    <measurement group_id="O2" value="4.05" lower_limit="2.54" upper_limit="11.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days in ICU</title>
        <time_frame>60 days from enollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Days in ICU</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.39" lower_limit="3.64" upper_limit="17.6"/>
                    <measurement group_id="O2" value="5.61" lower_limit="2.88" upper_limit="11.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <time_frame>28 days from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ICU Complications</title>
        <time_frame>daily through day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ICU Complications</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Fentanyl</title>
        <time_frame>during infusion of study medication up to day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Fentanyl</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Midazolam</title>
        <time_frame>during infusion of study medication through day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Midazolam</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days in Hospital</title>
        <time_frame>60 days from enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Days in Hospital</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.33" lower_limit="6.3" upper_limit="32.39"/>
                    <measurement group_id="O2" value="12.96" lower_limit="4.83" upper_limit="20.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Completing Activities of Daily Living</title>
        <description>activities of daily living: eating, bathing, dressing, grooming, toileting</description>
        <time_frame>daily through day 28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Completing Activities of Daily Living</title>
          <description>activities of daily living: eating, bathing, dressing, grooming, toileting</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Medication Effects</title>
        <time_frame>duration of infusion of study medication up to 28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexmedetomidine</title>
            <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
          <group group_id="O2">
            <title>Propofol</title>
            <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Medication Effects</title>
          <units>number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexmedetomidine</title>
          <description>Patients in this arm will receive continuous dexmedetomidine infusion (0.2 - 1.5 mcg/kg/hour) titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Dexmedetomidine: continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
        </group>
        <group group_id="E2">
          <title>Propofol</title>
          <description>Patients in this arm will receive propofol (5 - 50 mcg/kg/min) for sedation, titrated to the target Richmond Agitation Sedation Scale for the duration of mechanical ventilation or 7 days on study, whichever is first.
Propofol: continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
Fentanyl: 25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
Midazolam: 0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS&gt;+2)
Physical and Occupational Therapy: Daily therapy sessions targeting range of motion, strength, and mobility</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>John Kress</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-702-6790</phone>
      <email>jkress@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

